Shopping Cart
- Remove All
Your shopping cart is currently empty
LY-2584702 tosylate salt
LY-2584702 tosylate salt, a selective ATP-competitive p70S6K inhibitor, is being used in clinical trials for cancer treatment.
Catalog No. T1746Cas No. 1082949-68-5
Select Batch
Purity:98.5%
Contact us for more batch information
LY-2584702 tosylate salt
Catalog No. T1746Alias LY2584702 tosylateCas No. 1082949-68-5
LY-2584702 tosylate salt, a selective ATP-competitive p70S6K inhibitor, is being used in clinical trials for cancer treatment.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $31 | In Stock | |
| 2 mg | $44 | In Stock | |
| 5 mg | $72 | In Stock | |
| 10 mg | $122 | In Stock | |
| 25 mg | $228 | In Stock | |
| 50 mg | $378 | In Stock | |
| 100 mg | $538 | In Stock | |
| 500 mg | $1,150 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "LY-2584702 tosylate salt"
Sodium salicylate
Salicylic acid sodium salt, 2-Hydroxybenzoic acid sodium salt
T033554-21-7
Sodium salicylate (2-Hydroxybenzoic acid sodium salt), a metabolite of acetylsalicylic acid, can inhibit NF-kB and reduce oxidative stress.
- $45
Size
QTY
Bimiralisib
PQR309, PI3K-IN-2, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
T22651225037-39-7
Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.
Inquiry
MBM-55S
T119612083624-07-9In house
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
- $117
Size
QTY
Prexasertib dihydrochloride
Prexasertib HCl, LY2606368 (dihydrochloride), LY2606368
T43271234015-54-3
Prexasertib dihydrochloride (LY2606368) is an ATP-competitive CHK1 inhibitor (Ki: 0.9 nmol/L). in the cell-free assay, its IC50 values are 8 nM and 9 nM for CHK2 and RSK, respectively.
- $38
Size
QTY
Quercitrin
Cited
Xanthaurine, Sophoretin, Quercetin 3-rhamnoside, Meletin, 3-rhamnosyl quercetin
T2871522-12-3
Quercitrin (3-rhamnosyl quercetin) is a plant-derived flavonoid compound, displays antioxidant and anti-inflammatory activities. Quercitrin can be found in a number of food items such as garden tomato (var. ), German camomile, endive, and kiwi, which makes quercitrin a potential biomarker for the consumption of these food products.
- $42
Size
QTY
CitedCHIR-98014
CT98014, CHIR98014, CHIR 98014
T2608252935-94-7
CHIR-98014 (CT98014) is a selective GSK3 inhibitor; potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
- $39
Size
QTY
H-89 dihydrochloride Cited
Protein kinase inhibitor H-89 dihydrochloride, H 89 2HCl, 5-Isoquinolinesulfonamide
T6250130964-39-5
H-89 dihydrochloride (5-Isoquinolinesulfonamide) is a potent inhibitor of protein kinase A (PKA; IC50: 0.14 μM, Ki: 48 nM).
- $33
Size
QTY
CitedA-443654
T14072552325-16-3
A-443654, a pan-Akt inhibitor, exhibits equal potency against Akt1, Akt2, and Akt3 within cells (Ki=160 pM).
- $2,730
Size
QTY
CYC-116
T6458693228-63-6
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3α/β, CK2, Plk1 and SAPK2A. Phase 1.
- $33
Size
QTY
BI-D1870 Cited
T6171501437-28-1
BI-D1870 is a highly specific, blood-brain-permeable, and ATP-competitive inhibitor of the N-terminal AGC kinase domain of RSK, with IC50 values of 31 nM, 24 nM, 18 nM, and 15 nM for RSK1, RSK2, RSK3, and RSK4.
- $48
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | LY-2584702 tosylate salt, a selective ATP-competitive p70S6K inhibitor, is being used in clinical trials for cancer treatment. |
| Targets&IC50 | p70 S6K:4 nM |
| In vitro | In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. [1] LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. [2] |
| In vivo | LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87 mg glioblastoma and HCT116 colon carcinoma xenograft models. [1] |
| Alias | LY2584702 tosylate |
| Molecular Weight | 617.62 |
| Formula | C28H27F4N7O3S |
| Cas No. | 1082949-68-5 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 12 mg/mL (19.43 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy LY-2584702 tosylate salt | purchase LY-2584702 tosylate salt | LY-2584702 tosylate salt cost | order LY-2584702 tosylate salt | LY-2584702 tosylate salt chemical structure | LY-2584702 tosylate salt in vivo | LY-2584702 tosylate salt in vitro | LY-2584702 tosylate salt formula | LY-2584702 tosylate salt molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.